Thermo Fisher Scientific (TMO) EBITDA (2009 - 2026)

Thermo Fisher Scientific has reported EBITDA for 18 years, with the latest figure at $2.1 billion in Q2 2026.

• EBITDA for Q2 2026 came in at $2.1 billion, up 13.79% year-over-year; the trailing twelve-month figure through Jun 2026 was $8.1 billion (up 10.02% YoY), and the FY2025 annual result was $7.7 billion, up 5.57% from the prior year.
• EBITDA climbed to $2.1 billion in Q2 2026, from $1.9 billion in the prior quarter.
• Over five years, EBITDA peaked at $2.8 billion in Q2 2022 and troughed at $1.6 billion in Q2 2023.
• A 5-year average of $1.9 billion and a median of $1.9 billion in 2022 frame the typical range for EBITDA.
• The widest annual swing landed in 2023, when EBITDA plunged 44.59%; it then rose 15.34% in 2024.
• A 5-year view of EBITDA shows it stood at $1.9 billion in 2022, then fell by 0.38% to $1.9 billion in 2023, then grew by 8.74% to $2.0 billion in 2024, then grew by 11.86% to $2.3 billion in 2025, then slipped by 7.45% to $2.1 billion in 2026.
• Per Business Quant data, the three most recent EBITDA figures were $2.1 billion in Q2 2026, $1.9 billion in Q1 2026, and $2.3 billion in Q4 2025.